Age | 1.02 | 0.99–1.05 | 0.31 | | | |
Primary tumor vs. lung | | | 0.976 | | | |
Breast | 1.04 | 0.49–2.34 | | | | |
Other | 1.11 | 0.45–2.71 | | | | |
Prior stereotactic radiation treatment | 0.53 | 0.26–1.09 | 0.08 | | | |
Prior conventional radiation treatment | 4.55 | 1.97–10.50 | <0.01 | 3.46 | 1.27–9.44 | 0.015 |
Prior stereotactic and conventional radiation treatments | 0.75 | 0.30–1.83 | 0.52 | | | |
<6 mo from radiation treatment completion to PET | 3.64 | 1.54–8.62 | <0.01 | 1.02 | 0.36–2.90 | 0.97 |
≥12 mo from radiation treatment completion to PET | 0.68 | 0.34–1.37 | 0.28 | | | |
Steroid treatment during PET | 1.32 | 0.64–2.73 | 0.50 | | | |
Positive PET result (visual scale score of ≥2) | 6.95 | 2.86–16.93 | <0.01 | 6.24 | 2.51–15.47 | <0.01 |